Xeris Biopharma Holdings (XERS) Operating Income (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Operating Income came in at $7.9 million in Q1 2026, up 356.18% YoY from $1.7 million in Q1 2025, and down 52.81% on a QoQ basis from $16.8 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Operating Income (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Operating Income data on file, last reported at $7.9 million in Q1 2026.
- Quarterly Operating Income rose 356.18% year-over-year to $7.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.9 million (up 259.63% YoY) and the FY2025 annual result came in at $24.9 million, up 173.99% from the prior year.
- Operating Income slipped to $7.9 million in Q1 2026, from $16.8 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $16.8 million in Q4 2025 to a low of -$29.1 million in Q1 2022.
- A 5-year average of -$7.5 million and a median of -$9.8 million in 2023 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2024 — Operating Income sank 162.43% — and 2025, when it soared 898.99%.
- Tracing XERS's Operating Income over 5 years: stood at -$15.2 million in 2022, then surged by 35.13% to -$9.8 million in 2023, then jumped by 117.06% to $1.7 million in 2024, then soared by 898.99% to $16.8 million in 2025, then plunged by 52.81% to $7.9 million in 2026.
- The last three Operating Income figures came in at $7.9 million (Q1 2026), $16.8 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | -231.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 837.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.26 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 330.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 6.30 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 151.50 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 248.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.39 Bn | 79.59 Mn | 5.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.17 Mn |
| Mar 31, 2026 | 7.92 Mn |
| Dec 31, 2025 | 16.77 Mn |
| Sep 30, 2025 | 6.73 Mn |
| Jun 30, 2025 | 4.48 Mn |
| Mar 31, 2025 | -3.09 Mn |
| Dec 31, 2024 | 1.68 Mn |
| Sep 30, 2024 | -12.89 Mn |
| Jun 30, 2024 | -8.19 Mn |
| Mar 31, 2024 | -14.25 Mn |
| Dec 31, 2023 | -9.84 Mn |
| Sep 30, 2023 | -4.91 Mn |
| Jun 30, 2023 | -15.98 Mn |
| Mar 31, 2023 | -13.28 Mn |
| Dec 31, 2022 | -15.17 Mn |
| Sep 30, 2022 | -18.78 Mn |
| Jun 30, 2022 | -18.92 Mn |
| Mar 31, 2022 | -29.07 Mn |
| Dec 31, 2021 | -48.27 Mn |
| Sep 30, 2021 | -24.36 Mn |